Fig. 2: Administration of NECA suppresses ILC2 function.

a WT mice were challenged with PBS or IL-33 (500 ng/mouse/day) i.n for 3 consecutive days and simultaneously treated with NECA (0.1 mg/kg/day) or DMSO every day intraperitoneally, mice were sacrificed 24 h after last challenge. b Flow cytometric analysis of lung ILC2 (Gated in CD45⁺). Frequencies of Ki67⁺ ILC2 (c) and IL-5⁺IL-13⁺ ILC2 (d) in lung. e Eosinophils (EOS) (CD45⁺CD11c⁻Siglec-F⁺) levels in BALF were analyzed by flow cytometry. f The amount of IL-5 and IL-13 in BALF was examined by ELISA. g H&E staining of lung tissues (bars, 100 µm). Data are representative of two independent experiments (n = 4 for PBS groups, n = 6 for IL-33 groups). Error bars show mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001 by unpaired Student’s t test.